The End of AbbVie’s $200 Billion Monopoly Won’t Sink the Stock

[ad_1] The drugmaker is offering steep discounts on its immune-disease therapy Humira to protect market share this year. [ad_2] Source link

WSJ News Exclusive | AbbVie Aims for New Drugs to Boost Sales as Competitors Target Humira

[ad_1] Drugmaker AbbVie Inc. is looking for its next hit.  Now that its blockbuster immune-disease therapy Humira is facing lower priced competition, AbbVie is turning to a pair of next-generation…